Publications by authors named "Solange Pecout"
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Lancet Oncol
April 2024
Article Synopsis
- The study investigates the combination of the modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen with atezolizumab as a first-line treatment for advanced squamous cell carcinoma of the anus, building on mDCF’s established efficacy.
- Conducted across 21 centers in France, the phase 2 study randomly assigned participants to receive either the combination therapy or mDCF alone, focusing on 12-month progression-free survival as the primary endpoint.
- With 97 participants enrolled, the study found a median follow-up of 26.5 months, providing valuable insights into the potential benefits of combining immunotherapy with standard chemotherapy.
Backgrounds: Caregivers are essential in the care of a patient with digestive cancer. Considering their experience and needs is crucial.
Objectives: To explore the experience of caregivers of patients with digestive cancer and to compare the perspectives of patients and caregivers.
Considering the preferences in Shared Decision Making (SDM) of patients with Digestive Cancer (DC) is crucial to ensure the quality of care. To date, there is limited information on preferences in SDM of patients with DC. The objectives of this study were to describe digestive cancer patients' preference for involvement in therapeutic decision-making and to identify variables associated with these preferences.
View Article and Find Full Text PDFPurpose: The aim of this study was to explore the beliefs, perceptions and representations of patients in order to identify the determinants of oral anticancer drugs adherence and to take action in current practice to improve patient support in digestive oncology.
Methods: We constructed a semi-directed interview guide which aimed to explore the patient's relationship with medication, their health history, their experiences at the time of the announcement of treatment, their confidence, their fears, their motivations to adhere to their treatment and the constraints linked to their treatment. The data were analysed and discussed using a thematic approach.